A clinical trial of prostaglandin E2 to increase erythropoiesis in anemia of end stage renal disease. A preliminary report.
Prostaglandin E2 is known to stimulate erythropoiesis by different mechanisms. A clinical trial of prostaglandin E2 to stimulate erythropoiesis in four patients with anemia of end stage renal disease resulted in an increment in peripheral blood Burst Forming Units-Erythroid (BFU-E). This increase in erythroid progenitors returned to baseline with cessation of therapy. A significant increase in serum erythropoietin (EPO) activity was demonstrated in one patient and was noticeable in another. Side effects mainly consisted of local pain at the site of the infusion and vomiting.
D000293:Adolescent; D000740:Anemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D015232:Dinoprostone; D004920:Erythropoiesis / Q000187:drug effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D011458:Prostaglandins E / Q000627:therapeutic use*; D013997:Time Factors
D011458:Prostaglandins E; D015232:Dinoprostone